Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators
- PMID: 39570241
- DOI: 10.1016/j.jacc.2024.09.006
Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators
Abstract
Background: Predicting the clinical trajectory of individual patients with implantable cardioverter-defibrillators (ICDs) is essential to inform clinical care. Machine learning approaches can potentially overcome the limitations of conventional statistical methods and provide more accurate, personalized risk estimates.
Objectives: The authors sought to develop and externally validate a novel machine learning algorithm for predicting all-cause mortality and/or heart failure (HF) hospitalization in ICD patients with and without cardiac resynchronization therapy (CRT) using variables that are readily available to treating clinicians. We also sought to identify key factors that separate patients along a continuum of risk.
Methods: Random forest for survival, longitudinal, and multivariate (RF-SLAM) data analysis was applied to predict 3-month and 1-year risks for all-cause mortality and a composite outcome of death/HF hospitalization during the first 5 years of device implant. Models were trained using a nationwide cohort from the Veterans Health Administration. Three models were sequentially tested, and external validation was performed in a separate nonveteran clinical registry.
Results: The training and validation cohorts included 12,043 patients (age 67.5 ± 9.4 years) and 1,394 patients (age 66.3 ± 11.9 years), respectively. Median follow-up was 3.3 years for the training cohort and 3.6 years for validation cohort. The most accurate models for both outcomes included baseline demographics entered at the time of ICD implant (age, sex, CRT therapy) and time-varying ICD data with area under the receiver-operating characteristic curve for predicting death at 3 months (0.91; 95% CI: 0.87-0.94) and 1 year (0.80; 95% CI: 0.78-0.82); death/HF hospitalization at 3 months (0.81; 95% CI: 0.79-0.83) and 1 year (0.71; 95% CI: 0.70-0.72). Models demonstrated high discrimination and good calibration in the validation cohort. Additionally, time-varying physiologic data from ICDs, especially daily physical activity, had substantial importance in predicting outcomes.
Conclusions: The RF-SLAM algorithm accurately predicted all-cause mortality and death/HF hospitalization at 3 months and 1 year during the first 5 years of device implant, demonstrating good internal and external validity. Prospective studies and randomized trials are needed to evaluate model performance in other populations and settings and to determine its impact on patient outcomes.
Keywords: artificial intelligence; defibrillator; machine learning; remote monitoring; risk prediction.
Copyright © 2025 American College of Cardiology Foundation. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Data for this study was provided by Medtronic. However, Medtronic was not involved in the study design, analysis and interpretation of data, nor writing or publishing this study. Dr Rosman was sponsored by a grant from the National Heart, Lung, and Blood Institute (K23HL141644); has received research grants from Boston Scientific; has served on an advisory board for Biotronik; and has received consultancy fees from Pfizer and Biotronik. Drs Rosman and Wang are the inventors of the technology/ML software evaluated in this paper (U.S. Provisional Patent Application 63/684,842). Dr Gehi has received research funding from the Bristol Myers Squibb Foundation; and has received consultancy/speaker honoraria from Zoll Medical, Abbott, and iRhythm. Dr Lampert has served on an advisory board for Medtronic; and has received research funding and honoraria from Abbott (both completed 5/22). Dr Sears has received honoraria/consulting fees from Medtronic, Abbott, Zoll Medical, Milestone Pharmaceutical, Thryve, and Tenaya. Dr Sears has received research grants from CVRx, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The views expressed in this paper are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; the U.S. Department of Health and Human Services; or the U.S. Department of Veterans Affairs.
MeSH terms
LinkOut - more resources
Miscellaneous